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B lymphocytes from patients suffering from systemic 
lupus erythematosus show increasing rates of sponta-
neous transformation in prolonged cultivation (144 hr). 
An additional B cell stimulation could be detected follow-
ing the addition of sera from lupus erythematosus pa-
tients (isolated during the acute phase of disease) to the 
culture medium. In addition enriched mitogenic serum 
components from lupus sera increase the :IH-thymidine 
uptake of Brucella abortus primed B cells of healthy 
controls. The incorporation of 3H-thymidine with respect 
to the Brucella antigen concentration is described. 
Systemic lupus erythematosus (SLE) represents an immune 
complex disease and belongs to the autoimmune diseases. A 
number of immunological peculiarities associated with SLE 
have been demonstrated: antibodies against desoxyribonucleic 
acid, ribonucleic acid, and ribonucleoprotein [1]; an increased 
occurrence of antigen-antibody complexes in the serum (2]; a 
reduction of complement factors during exacerbation [3]; anti-
bodies against erythrocytes [4]; thrombocytes [5], and leuko-
cytes (6]. It is an established fact that such autoantibodies are 
of pathogenic significance. It is, however, not known why they 
are formed in SLE patients. There is evidence that suppressor 
T cells or a soluble immune response suppressor substance may 
be deficient in autoimmune diseases [7,8]. Although the precise 
function of the suppressor T cells in man is unknown, they 
seem to play an important role in the immunologic regulation 
and in the prevention of autoantibody production. In the acute 
phase of SLE mitogenic components were detected in the sera 
which also induce an increase in the lymphocytic transforma-
tion of autologous and allogenic lymphocytes [9,10]. During the 
transformation, a lysis of autologous target fibroblasts occurs. 
The stimulation rate is still decreased by sera taken n·om SLE 
patients in remission [9J In this study the influence of mitogenic 
serum components on 3H-thymidine incorporation in DNA of 
autologous and allogenic B lymphocytes is investigated. Fur-
thermore, the activation of antigen primed allogenic B cells in 
the presence of mitogenic serum components is described. A 
hypothesis concerning the pathogenic action of mitogenic serum 
components (polyclonal B cell activators) in SLE is presented. 
MATERIALS AND METHODS 
All patients had multiple involvements compatible with SLE and 
fulfilled ARA preliminary criteria [11] for the classification of SLE. 
Patients were considered as clinically active if 3 or more of the following 
symptoms were present: butterfly rash, arthritis or persistent ru·thralgia, 
pleural effusion, myocarditis, marked increase of proteinuria, throm-
bocytopenia, lymphocytopenia, anti-DNA antibodies, and antinucleru· 
antibodies (Table). 
Manuscript received July 21, 1980; accepted for publication June 19, 
1981. 
Reprint requests to: Dr. W. Diezel, Department of Dermatology, 
Humboldt University, Schumannstr. 20/21, DDR-1040 Berlin. 
Abbreviations: 
SLE: systemic lupus erythematosus 
87 
Determination of Antinuclear and Anti-DNA Antibodies 
Serum antinucleru· antibody determinations utilized snap-frozen 
cryostat sections of canine esophagus as a somce of nuclei and flum·es-
cein-conjugated rabbit antihuman gamma-globulin was used as de-
scribed previously [12] . Anti-DNA antibodies were determined by the 
method of Pincus [13] using 125Iodine-labeled, single- tranded, calf-
thymus DNA in the precipitation technique of Farr [14l 
Lymphocyte Preparation 
T cells were purified from normal and SLE human blood lympho-
cytes by neuraminidase-treated sheep RBC rosette formation (15) and 
they contained less than 1% B cells (surface Ig+ cells by immunofluo-
rescence). B-enriched cell suspensions were obtained according to 
Gupta, Miescher, and Good [16]. B lymphocytes were contaminated by 
6-10% T lymphocytes. 
Lymphocyte Cultures 
Cells were suspended in RPMI-1640 medium in triplicate in 0.2 ml 
vol (Falcon 3040 dishes) conta ining 2 X 105 lymphocytes and 0.04 ml 
(20%) serum. Proliferation in cultures was measured as incorporation 
of "H-thymidine (Isocommerz GmbH, Dresden) by adding 1 JLCi radio-
labeled nucleotide during the last 15 hT of cultm e. Tritium incorpora-
tion was measured by liquid scintillation counting in a Tricru·b 3375 
Liquid scintillations counter. B and T lymphocytes of SLE patients 
were cultw-ed with the particular autologous serum and with pooled 
AB/ Rh control serum, respectively. B lymphocytes of controls (AB/ 
Rh) were cultured with pooled SLE serum (sera of SLE patients shown 
in t he Table). Complement factors were inactivated in a ll sera used (30 
min at 56 °C). Cultmes were harvested after 144 hr. 
Gel Filtration Expe1'iments 
To enrich mitogenic serum components pooled SLE serum (sera of 
SLE patients shown in the Table) was added to a sephadex G-200 
column (5 X 70 em, Pharmacia, Uppsala, Sweden) and eluted with 
phosphate buffered saline, pH 7.0. 10 ml serum was applied. The last 
peak of the eluate (enriched mi togenic components) was collected and 
concentrated using a 10 PM Diaflo ultraftltration membrane (Amicon 
Corp., Lexington, Mass.). Identical serum proteins were isolated from 
pooled AB/ Rh serum for control experiments. 
Aritifical Immunization 
The ru·tificial in1munization of 5 human volunteers (AB/ Rh) with 
Brucella abortus (Strain B 19 R) antigen was performed as described 
previously [17]. Bacterial suspensions (1.0 mg antigen suspended m 
phosphate buffered saline) were injected in tramusculru·ly. 
Stimulation of Brucella Primed B Lymphocytes 
B lymphocytes of 5 immunized volunteers were isolated 3 weeks 
after the immunization. 10-300 JLg Brucella antigen and 20 mg protem 
(enriched mitogenic serum components from SLE) were added to the 
lymphocyte cultures (Brucella primed B lymphocytes). In controls 20 
mg protein from AB/ Rh serum (last peak of the eluate following 
Sephadex G-200 filtration of 10 ml pooled AB/ Rh serum) was added. 
Mean values and standard deviations of each 5 duplicates (5 immunized 
human volunteers) are presented. Furthermore, control experiments 
were performed at the time prior to the immunization with B lympho-
cytes of the same human volunteers (cultures of non-Brucella primed 
B lymphocytes and addition of mitogenic serum components from 
SLE). 
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Protein 
This was assayed according to the proceduxe of J anatova, Fuller, and 
Hunter (18) with bovine serum albumin as standard. 
RESULTS 
After a 6-day incubation period of B lymphocytes of SLE 
patients and normal controls with SLE sera (containing the 
mitogenic principle), the rates of incorporated ~H-thymidine 
were increased (Fig 1, IA and VB) . The T lymphocytes of both 
the patients (Fig 1, IliA) and the controls were not stimulated 
(data not shown) . 
After the incubation of B lymphocytes of both the SLE 
patients and controls with sera fro m normal donors (AB/ R h) 
the B cells from SLE patients were more stimulated than the 
Laboratory data of some acu.te phase-SLE patients investigated 
Patient No." Antinuclear anti- % of 0.1 ug of 12''J Leukocytes pe r /LI bodies ssDN A' bound '' plasma 
1. EM 1:400 22.8 3,600 
2. LK 1:100 37.1 4,100 
3. sw 1:1600 65.4 3,200 
4. OA 1:400 14.3 4,600 
5. SA 1:200 43.7 6,800 
" Sex: female in all cases. 
'' Controls: 10.2 ± 7.6% (mean value and standard deviation by 120 
healthy persons). 
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FIG l. Uptake of "H-thymidine by B lymphocytes and T lympho-
cytes of SLE patients (A) and contro ls (B) following addition of SLE 
sera and control (AB/Rh) sera. •. B lymphocytes/SLE serum; D, B 
lymphocytes/control serum; e, T lymphocytes/SLE serum; 0 , T lym-
phocytes/control serum. Mean values and standard deviations (cpm): 
I A: 20, 100 ± 6,200; II A: 9,000 ± 8,000; III A: 1,800 ± 600; IV A: 1100 
± 400; VB: 9,500 ± 2,600; VI B: 1,800 ± 400. +U-tests (Mann and 
Whitney): I A l ii A p < 0.05; V B! Vl B p < 0.001; T A / Ill A p < O.Dl; 
Ill A / I V A p < 0.01; II A / VI B p < 0.05. 
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control cells (Fig 1, IIA/VIB , p < 0.05). lzui , McConahey, and 
Dixon [19] and Cohen and Ziff [20] reported on a similarly 
increased spontaneous activity of B cells in mice with a spon-
taneously autoimmune disease. Gershwin et al [21] interpreted 
this effect as an evidence of a B cell defect. As shown (Fig 1, 
IA ! IIA, p < 0.05) the spontaneous stimulation was increased in 
the presence of SLE serum. This result demonstrates that the 
mitogenic serum components in acute SLE have an additional 
affect on B cell stimulation. 
After the sensit ization of B lymphoctyes against Brucella 
antigen (isolation of the lymphocytes following an artificial 
immunization of controls with Brucella abortus ant igen) an in 
vitro incubation with Brucella antigen was performed. An in-
creased uptake of '1H-thymidine after the addition of the en-
riched mitogenic SLE serum components compared to AB (Rh) 
control serum components could be observed (Fig 2). 
As shown in Fig 2 the uptake of 3H-thymidine by the sensi-
tized lymphocytes decreased at antigen concentration in excess 
(100 !J.g) . The decrease _was not influenced by the mitogenic 
principle of the SLE sera. This effect is not due to inhibitory 
factors in the antigen preparation because the stimulation rates 
of the non-Brucella -primed B cells were not diminished. There 
is no explanation for the decreased 3H-thymidine incorporation 
at higher antigen concentrations (100-300 !J.g) at the moment. 
DISCUSSION 
The occurrence of mitogenic components in serum of SLE 
patients agrees with the observation of an increased sponta-
neous activity of antibody-forming cells in the peripheral blood 
in acute SLE [22]. The present data demonstrate that the 
mitogenic serum components have an addit ional affect on B 
cell stimulation, and, furthermore, that the enriched mitogenic 
principle increases the uptake of 3H-thymidine by Brucella 
antigen primed allogenic B cells in a nonspecific manner. Non-
specific mitogenic factors are secreted both by macrophages 
[23) and lymphocytes [24-26]. Fw-thermore, bacterial compo-
nents (capsular polysaccharides [27]), lipopolysaccharides [28-
31] and Fe fragments derived from human IgG stimulate mac-
rophages [32] have a nonspecific mitogenic effect for human B 
cells. 
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FIG 2. Increased uptake of "H-thymidine by sensit ized a llogenic B 
lymphocytes fo llowing addit ion of the specific antigen and mi togenic 
serum components. Mean values and standard deviat ions of each 5 
duplicates (see "Materia l and Methods"). e, Brucella-primed control 
lymphocytes/Brucella antigen I enriched mitogenic SLE serum com-
ponents. 0 , Brucella-primed control lymphocytes/Brucella antigen/ AB 
(Rh) control serum components. X, Non-Brucella-primed control lym-
phocytes/Brucella antigen/enriched mitogenic SLE serum compo-
nents. 3H-thymidine incorporation of controls (nonprimed lympho-
cytes/normal serum/ Brucella ant igen) : 100 IJ.g antigen: 1,400 ± 500 
cpm; 300 /-lg ant igen:1,500 ± 400 cpm. 
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FIG 3. Hypothetical aspects concerning the influence of non-specific 
mitogenic components on the B cell stimu lation. B cell stimulation in 
t he presence of low (B) and high (A) concentrations of nonspecific 
mitogenic serum components. 
We assume that the production of autoantibodies in SLE 
patients is due to the fact that the activity of a mitogenic serum 
principle predominates or that the functional effectiveness of 
suppressor T lymphocytes is reduced. The activation of B 
lymphocytes is caused by the interaction between a polyvalent 
ligand (antigen) and t h e receptors of the lymphocyte membrane 
(1st signal). An increased stimulation of the B cells may also be 
induced by the interaction between additional factors and spe-
cific membrane receptors (2nd signal ) [33]. 
We assume that there results a lymphocyte stimulation in 
low concentrations of mitogenic serum components according 
to the curve shown in Fig 3B. Under these conditions mainly B 
lymphocytes with high affinity for the antigen should be stim-
ulated. Antibodies with similar high affinity and immune com-
plexes possessing high avidity should be generated. These com-
plexes do not have any pathogenic importance [34,35]. In con-
trast B cells will be polyclonally stimulated by nonspecific 
mitogenic components [29-31]. The stimulation kinetics should, 
then, correspond to the curve shown in Fig 3A. At low antigen 
concentrations lymphocytes with low affinity for the antigen 
are stimulated. The resulting antibodies show a low affinity to 
the related antigen, and the immune complexes possess a low 
avidity. These immune complexes might be of considerable 
pathogenic importance (34,35). 
In t h e sera of SLE patients a number of autoantibodies can 
be demonstrated. According to the presented hypothesis their 
existence could be explained as follows: SLE patients are 
thought to be able to produce antibodies against "self." Some 
results published recently, in fact, can be interpreted th at every 
organism is potentially able to produce autoantibodies [31,36]. 
An increased concentration of mitogenic components in the 
microenvironment of these B lymphocytes might be able to 
induce the time-limited production of autoantibodies. There-
fore, the increased occurrence of polyclonal B lymphocyte 
activators in sera of SLE patients could be of significant impor-
tance for autoimmunity in SLE. 
We thank Ms. Angelika Zwirner for expert technical assistance. 
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Announcement 
The Standardization Subcommittee of the International Society for Bioengineering and the Skin will 
be considering temperature measurement of the skin in vivo. We would be pleased to hear from individuals 
who work in this area and receive evidence concerning the production of standards. Write to Professor R. 
Marks, Professor of Dermatology, Department of Medicine, Welsh National School of Medicine, H eath 
Park, Cardiff, CF4 4XN . UK. . 
